Ocular Therapeutix

Ocular Therapeutix, Inc. engages in the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company's products include ReSure Adherent Ocular Bandage, a synthetic ocular bandage for ophthalmic surgery; ReSure Sealant, a synthetic and biocompatible hydrogel that creates a temporary, soft, and lubricious surface barrier to protect clear corneal incisions in the immediate post-operative period; and prostaglandin analog punctum plugs that are hydrogel-based punctum plug depots to deliver prostaglandin analogs to treat glaucoma.

Company Growth (employees)
Type
Public
HQ
Bedford, US
Founded
2006
Size (employees)
118 (est)
Website
ocutx.com
Ocular Therapeutix was founded in 2006 and is headquartered in Bedford, US

Key People/Management at Ocular Therapeutix

Antony Mattessich

Antony Mattessich

Chief Executive Officer
Fred Khosravi

Fred Khosravi

Co - Founder, Director & Chairman

Ocular Therapeutix Office Locations

Ocular Therapeutix has an office in Bedford
Bedford, US (HQ)
36 Crosby Drive,

Ocular Therapeutix Financials and Metrics

Ocular Therapeutix Financials

Ocular Therapeutix's revenue was reported to be $1.8 m in FY, 2015
USD

Net income (Q1, 2017)

(16 m)

Market capitalization (13-Nov-2017)

154.7 m

Cash (30-Jun-2017)

63 m
Ocular Therapeutix's current market capitalization is $154.7 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

772 k1.8 m

Revenue growth, %

127%

Net Income

(28.6 m)(39.7 m)(44.7 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(13.4 m)(20.7 m)(7.6 m)(17.6 m)(29.1 m)(10.8 m)(22.3 m)(31.9 m)(16 m)
USDFY, 2014FY, 2015FY, 2016

Cash

37.4 m30.8 m32.9 m

Accounts Receivable

329 k193 k250 k

Inventories

893 k1.6 m1.4 m

Current Assets

76.2 m107 m69.9 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

19.9 m80.9 m12.5 m78.7 m41.2 m46.2 m48.2 m52.2 m54.7 m63 m

Accounts Receivable

60 k53 k352 k164 k189 k227 k223 k243 k244 k211 k

Inventories

109 k117 k158 k145 k147 k127 k149 k126 k96 k90 k

Current Assets

22.6 m82.3 m69.5 m126.6 m115.9 m97.1 m85 m76.8 m83.3 m68.3 m
USDFY, 2014FY, 2015FY, 2016

Net Income

(28.6 m)(39.7 m)(44.7 m)

Depreciation and Amortization

547 k754 k881 k

Accounts Receivable

(79 k)136 k(57 k)

Inventories

(36 k)(53 k)924 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(13.4 m)(20.7 m)(7.6 m)(17.6 m)(29.1 m)(10.8 m)(22.3 m)(31.9 m)(16 m)(34.7 m)

Depreciation and Amortization

244 k383 k173 k360 k554 k205 k412 k628 k261 k615 k

Accounts Receivable

190 k197 k(23 k)165 k140 k(34 k)(30 k)(50 k)6 k39 k

Inventories

(109 k)(117 k)(25 k)(12 k)(14 k)7 k(15 k)8 k17 k23 k
Y, 2017

Financial Leverage

1.7 x
Show all financial metrics

Ocular Therapeutix Market Value History

Ocular Therapeutix's Web-traffic and Trends

Ocular Therapeutix News and Updates

Unable to head off the FDA, Ocular Therapeutix gets second CRL for eye drug

Manufacturing has for the second time stepped on Ocular Therapeutix’s chance of an FDA approval for its new drug for pain following eye surgery.

Ocular Therapeutix Company Life and Culture

You may also be interested in